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Abnormal epidermal proliferation and di¡erentiation
characterize the in£ammatory skin disease psoriasis.
Here we demonstrate that expression of PPARd mRNA
and protein is markedly upregulated in psoriatic lesions
and that lipoxygenase products accumulating in psoria-
tic lesions are potent activators of PPARd. The expres-
sion levels of NF-jB p50 and p65 were not signi¢cantly
altered in lesional compared with nonlesional psoriatic
skin. In the basal layer of normal epidermis both p50
and p65 were sequestered in the cytoplasm, whereas
p50, but not p65, localized to nuclei in the suprabasal
layers, and this distribution was maintained in lesional
psoriatic skin. In normal human keratinocytes PPAR
agonists neither impaired IL-1b-induced translocation
of p65 nor IL-1b-induced NF-jB DNA binding. We
show that PPARd physically interacts with the N-term-
inal Rel homology domain of p65. Irrespective of the
presence of agonists none of the PPAR subtypes de-
creased p65-mediated transactivation in keratinocytes.
In contrast p65, but not p50, was a potent repressor of
PPAR-mediated transactivation. The p65-dependent
repression of PPARd- but not PPARa- or PPARc-
mediated transactivation was partially relieved by
forced expression of the coactivators p300 or CBP. We
suggest that de¢cient NF-jB activation in chronic psor-
iatic plaques permitting unabated PPARd-mediated
transactivation contributes to the pathologic pheno-
type of psoriasis. Key words: IjBa/immunohistochemistry/
keratinocytes/NF-jB p50/NF-jB p65. J Invest Dermatol
121:1104 ^1117, 2003
P
soriasis is an in£ammatory skin disease that a¡ects ap-
proximately 2% of the population in Europe and
Northern America. Major characteristics of psoriasis
are hyperproliferation and accumulation of numerous
in£ammatory mediators in the involved areas (Ham-
marstrom et al, 1975; Kragballe and Fallon, 1986; Stern, 1997).
Cytokines and in£ammatory mediators contribute to the
establishment and maintenance of the pathologic phenotype of
psoriasis lesions by promoting lymphocyte in¢ltration and acti-
vation, and by directly modulating keratinocyte proliferation
and di¡erentiation (Uyemura et al, 1993; Terui et al, 2000). Classi-
cal nuclear hormone receptors such as the retinoid and vitamin D
receptors are critically involved in the modulation of epidermal
di¡erentiation and function (Pillai and Bikle, 1991; Li et al,
2000a). Accordingly, naturally occurring retinoids and vitamin
D or synthetic analogs have been used widely in the treatment
of psoriasis due to their pro-di¡erentiating and antiproliferative
e¡ects on keratinocytes and their ability to modulate T cell in¢l-
trates (Berth-Jones and Hutchinson, 1992; Itin et al, 1994).
Several lines of evidence have indicated that members of the
peroxisome proliferator-activated receptor (PPAR) and liver X
receptor subfamilies of the nuclear hormone receptors are of im-
portance for epidermal di¡erentiation and barrier formation
(Hanley et al, 1997; 1998; 2000; Komuves et al, 1998; Rivier et al,
1998; 2000), and it has been suggested that PPARa plays an
important role in lipid metabolism in reconstructed epidermis
(Rivier et al, 2000). Interestingly, systemic administration of the
PPARg-selective ligand troglitazone was reported to improve
psoriasis and reverse the abnormal phenotype of transplanted
psoriatic skin (Ellis et al, 2000).
Three PPAR subtypes, a, d (b), and g have been identi¢ed,
each characterized by distinct tissue distribution and functions
(Willson et al, 2000). PPARs regulate gene expression by binding
with their heterodimeric partner, retinoid X receptors, to speci¢c
peroxisome proliferator response elements (PPRE) in responsive
genes. Fatty acids and their derivatives, including hydroxylated
eicosanoids and prostaglandins, as well as several synthetic ligands
have been shown to activate the di¡erent PPAR subtypes with
variable e⁄cacy and potency (Forman et al, 1995; Kliewer et al,
1995).
All three PPAR subtypes are expressed in mouse epidermis
during fetal development, but shortly after birth expression of
PPARs become undetectable in the interfollicular epidermis
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(Michalik et al, 2001). Interestingly, expression of PPARa and
PPARd is induced in response to skin injury, where PPARawas
shown to be important during the initial in£ammatory phase and
PPARdwas shown to play a pivotal role for cell migration and
survival during re-epithelialization (Michalik et al, 2001; Tan
et al, 2001; Di-Po|« et al, 2002).
In human skin all PPAR subtypes are expressed also in the
adult interfollicular epidermis with PPARd being by far the most
abundantly expressed PPAR subtype (Rivier et al, 1998; Matsuura
et al, 1999;Westergaard et al, 2001). Furthermore, treatment of nor-
mal human keratinocytes in vitro with a PPARd-selective ligand
induces expression of keratinocyte di¡erentiation marker genes
suggesting that PPARd plays a role in di¡erentiation of human
keratinocytes (Westergaard et al, 2001).
The ubiquitously expressed transcription factor nuclear factor
kB (NF-kB) is a key player in the regulation of immune and in-
£ammatory responses (Barnes and Karin, 1997; Baeuerle, 1998),
and numerous ¢ndings have indicated that NF-kB also plays a
pivotal role in epidermal biology (Kaufman and Fuchs, 2000;
Fuchs and Raghavan, 2002). Direct or indirect disruption/modu-
lation of components involved in NF-kB activation (Seitz et al,
1998; 2000a; 2000b; van Hogerlinden et al, 1999; Hu et al, 1999;
Li et al, 1999; Takeda et al, 1999) was reported to exert a profound
in£uence on epidermal proliferation, di¡erentiation, and/or
homeostasis, and in the absence of proper activation of NF-kB,
terminal di¡erentiation was perturbed. Interestingly, mice with
an epidermis-speci¢c deletion of IKK2 (IKKb) were born with
a histologically normal skin, but epidermal hyperplasia and in-
£ammation with impaired di¡erentiation developed within the
¢rst week after birth (Pasparakis et al, 2002). The epidermal hy-
perplasia was shown not to result from cell-autonomous hyper-
proliferation of keratinocytes, but appeared to be dependent on
a reaction driven by the innate immune system (Pasparakis et al,
2002). In addition, the recent and surprising ¢nding that IKK1
(IKKa) regulates epidermal di¡erentiation in a manner indepen-
dently of NF-kB via production of a secreted di¡erentiation-in-
ducing factor (Hu et al, 2001) indicates that the way that
components of the NF-kB systems coordinate cell cycle withdra-
wal, di¡erentiation, and protection from apoptosis is far more
complex than previously anticipated.
Because recent evidence points to a role of PPARd in cellular
proliferation (He et al, 1999; Jehl et al, 2000; Hansen et al, 2001)
and an earlier report (Rivier et al, 1998) suggested that expression
of PPARdwas increased in lesional psoriatic skin, we decided to
investigate whether expression of the di¡erent PPAR subtypes
was aberrantly regulated in hyperproliferative lesional psoriatic
skin. In addition, as substantial evidence suggests that at least
PPARa and PPARg, apart from playing important roles in lipid
homeostasis, are involved in the modulation of in£ammatory re-
sponses via negative cross-talk with transcription factors such as
NF-kB and activating protein 1 (Devchand et al, 1996; Chinetti
et al, 1998; Jiang et al, 1998; Ricote et al, 1998; Staels et al, 1998; De-
lerive et al, 1999; Su et al, 1999; Straus et al, 2000), we investigated
the interplay between PPAR and NF-kB in keratinocytes.
MATERIALS AND METHODS
Biopsies Keratome biopsies from lesional and nonlesional psoriatic skin
in patients with psoriasis vulgaris were obtained as described previously
(Fogh et al, 1989). In addition, excision biopsy specimens from lesional
psoriatic skin before and after treatment at the Dead Sea were obtained.
Biopsies were taken in local anesthesia 1% lidocain cum epinephrine.
Protocols were approved by the local ethical committee before biopsies
were taken and written consent was provided by patients before experi-
ments were initiated.
Cell culture and interleukin 1b (IL-1b) stimulation Keratinocytes
from adult humans (controls) were isolated from human skin obtained
after plastic surgery. First passage keratinocytes were grown in
Keratinocyte-SFM (Gibco BRL/Life Technologies, Gaithersburg, MD)
supplemented with 50 mg per ml bovine pituitary extract, 5 ng per ml
human recombinant epidermal growth factor, and 5 mg per ml
gentamycin and replated in 75 cm2 culture £asks (Nunc, Roskilde,
Denmark). Cells were grown at 5% CO2 and 371C. In experiments
including stimulation with IL-1b, pretreatment with Keratinocyte-SFM
containing selective PPAR ligands was initiated when the cultures were at
approximately 30% con£uency. Control cells not treated with PPAR
ligands received similar volumes of vehicle (0.1% dimethylsulfoxide
(DMSO)). Cells were incubated for 24 h (for electrophoretic mobility
shift assay (EMSA) and immunostaining) or 2 h (for RT-PCR) with the
ligands before the addition of IL-1b (10 ng per ml). The cells were
harvested 30 min (for EMSA and immunostaining) or 3 h (for RT-PCR)
after addition of IL-1b. HaCaT cells were cultured in Dulbecco’s modi¢ed
Eagle’s medium (Gibco BRL/Life Technologies) with 10% fetal bovine
serum and antibiotics (100 U per mL penicillin, 1 mg per mL streptomycin
sulfate) in a humidi¢ed atmosphere of 5% CO2 at 371C. Medium was
changed every second day. BRL49653 was kindly provided by Dr J.
Fleckner (Novo Nordisk, Bagsvrd, Denmark) and L165041 was kindly
provided by Dr D.E. Moller (Merck Research Laboratories, Rahway, NJ).
Wy14643 was purchased from Calbiochem (San Diego, CA).
Plasmids pcDNA3.1(þ )hPPARa, pcDNA3.1(þ )hPPARd, and
pcDNA3.1(þ )hPPARg1were constructed as described previously (Weste-
rgaard et al, 2001). The pcDNA3.1(þ )hPPARa(DAB) expression plasmid
was constructed by ampli¢cation of the hPPARa cDNA from
pCR2.1hPPARa by PCR using XbaI/BamHI tagged primers (upstream
primer, 50 -AATTGGATCCACCATGGGAGCATTGAACATCGAATG-30;
downstream primer, 50 -CTAGTCTAGAAACTCAGTACACGTCCCTG-
30) and inserted into the XbaI/BamHI sites of pcDNA3.1(þ ). The
pcDNA3.1(þ )hPPARd(DAB) expression plasmid was constructed by
ampli¢cation of the hPPARd cDNA from pCR2.1hPPARd by PCR
using XbaI/BamHI tagged primers (upstream primer, 50 -AATTGGATC-
CACCATGGGCAGCCTCAACATGGAGTGC-30; downstream primer,
50 -CTAGTCTAGACCGTTAGTACATGTCCTTG-30) and inserted into
the XbaI/BamHI sites of pcDNA3.1(þ ). pcDNA3.1(þ )hPPARg(DAB)
expression plasmid was constructed by ampli¢cation of the hPPARg
cDNA from pCR2.1hPPARg by PCR using Asp718/XbaI tagged primers
(upstream primer, 50 -CTAGTCTAGACTGCTAGTACA-AGTCCTTG-30;
downstream primer, 50 -CTAGTCTAGACCGTTA-GTACATGTCCTTG-
30) and inserted into the Asp718/XbaI sites of pcDNA3.1(þ ). The pM1-
hPPARa(LBD)/Gal4(DBD), pM1-hPPARd(LBD)/Gal4(DBD), and pM1-
hPPARg(LBD)/Gal4(DBD) constructs were kindly provided by Dr J.
Fleckner. The PPREx3-tk-luc reporter containing three copies of the
PPRE from the acyl-CoA oxidase promoter and the UASx4luc reporter
were kindly provided by Dr R.M. Evans (Howard Hughes Medical
Institute, La Jolla, CA). CMV-b-galactosidase (Clontech, Palo Alto, CA)
and the SV40-b-galactosidase (Promega, Madison,WI) vectors were used
for normalization. The reporter construct containing three tandem copies
of the kB site (p(kB)3-lucþ , Stratagene, La Jolla, CA) has been described
previously (Delerive et al, 1999). p65-CMV2-Flag and p50-CMV2-Flag
were kindly provided by Dr A. Baldwin Jr (University of North Carolina
at Chapel Hill, NC). pGEX, pGEXp65(1^305), and pGEXp65(354^551)
used in pull-down experiments were kindly provided by Dr H. Sakurai
(Tanabe Seiyaku, Japan) and have been described elsewhere (Sakurai et al,
1999).
Transactivation assays All transfections were carried out in 12-well
plates, and the amounts given refer to the amount of plasmid added per
well. Transfection studies with full-length hPPAR were performed in
HaCaT cells as described elsewhere (Westergaard et al, 2001) using the
BES-CaCl2 method. Transfections with hPPAR(DAB) were carried out
using 0.75 mg PPREx3-tk-luc in combination with expression vectors for
hPPARa (0.01 mg), hPPARd (0.05 mg), hPPARg1 (0.05 mg), hPPARa(DAB)
(0.01 mg), hPPARd(DAB) (0.05 mg), or hPPARg(DAB) (0.05 mg). When
using PPAR-Gal4 fusion constructs, 0.75 mg UASx4luc was used in com-
bination with hPPARa(LBD)/Gal4(DBD) (0.125 mg), hPPARd(LBD)/
Gal4(DBD) (0.125 mg), or hPPARg1(LBD)/Gal4(DBD) (0.125 mg). Vehicle
(0.1% DMSO) or ligands were added as indicated. 8(S)HETE, LTB4,
12(S)HETE, 12(R)HETE, 15(S)HETE, and 13(S)HODE were obtained
from Cayman Chemical (Ann Arbor, MI). Normal human keratinocytes
were transiently transfected using E¡ectene (Qiagen, Valencia, CA). Two
series of transfection studies with hPPARa, hPPARd, or hPPARg1, and
p65 of NF-kB were performed using reporter constructs containing (1)
three tandem copies of the kB binding site (p(kB)3-lucþ ) or (2) three
tandem copies of the PPRE (PPREx3-tk-luc), as stated in the ¢gure
legends. Transfection studies using the reporter construct p(kB)3-lucþ
(50 ng) were performed in the presence of 6 ng p65 in combination with
18 and 60 ng hPPARa, hPPARd, or hPPARg1. 110 ng of the SV40-b-
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galactosidase construct were included for normalization.Transfections with
the PPAR-responsive promoter construct were carried out using 160 ng
PPREx3-tk-luc in the presence of 0.625 ng hPPARa, 62.5 ng hPPARd,
or 62.5 ng hPPARg1 in combination with 0.1, 0.5, 2.5, and 12.5 ng p65
expression vector. 110 ng of the SV40-b-galactosidase construct were
added for normalization. Transfection studies with the PPAR and the p50
construct were performed using the following combinations of PPREx3-
tk-luc, hPPAR constructs, and p50 expression vector: hPPARa (0.625 ng),
PPREx3-tk-luc reporter (160 ng), and p50 (0.1, 0.5, and 2.5 ng); hPPARd
(20 ng), PPREx3-tk-luc reporter (130 ng), and p50 (3.2, 16, 80 ng); or
hPPARg1 (40 ng), PPREx3-tk-luc reporter (102.5 ng), and p50 (6.4, 32,
160 ng). 110 ng of the SV40-b-galactosidase construct were added for
normalization. In all transfections empty expression vector was added to
ensure equal promoter load. Six hours following transfection fresh
medium was added and cells were subsequently incubated for about 20 h
in Keratinocyte-SFM containing either vehicle (0.1% DMSO), 10 mM
Wy14643, 5 nM L165041, or 1 mM BRL49653. In the IL-1b stimulation
experiments, normal human keratinocytes were transfected with 75 ng
p(kB)3-lucþ and 225 ng SV40-b-galactosidase construct. Seven hours
following transfection the cells were pretreated with vehicle (0.1%
DMSO), 5 nM L165041, or 1 mM BRL49653 for 2 h and subsequently
incubated for another 3 h with IL-1b (10 ng per mL). In the coactivator
titration experiment 293 cells were transiently transfected using the
calcium phosphate coprecipitation protocol. 750 ng PPREx3-tk-luc
reporter were used with di¡erent combinations of expression vectors:
hPPARa (1.25 ng), hPPARd (62.5 ng), hPPARg1 (62.5 ng), 12.5 ng p65 as
indicated, and CPB or p300 (125, 375, 1125 ng). 50 ng of the SV40-b-
galactosidase construct were cotransfected for normalization. Medium was
changed after 5 h, and the cells were subsequently incubated for
approximately 16 h with medium containing Wy14643 (30 mM), L165041
(500 nM), BRL49653 (1 mM), or vehicle (0.1% DMSO). The luciferase
and b-galactosidase activities in cell lysates were determined by standard
techniques. Luciferase activities were normalized to b-galactosidase
activities. All transfections were performed in duplicate or triplicate,
measured in duplicate, and repeated two to four times.
RNA puri¢cation TRIZOL reagent was used for the isolation of total
RNA as recommended by the manufacturer (Gibco BRL/Life Tech-
nologies). The integrity of all RNA samples was con¢rmed by electro-
phoresis in denaturing formaldehyde-containing gels.
Multiplex RT-PCR Multiplex RT-PCR was carried out as described
previously (Westergaard et al, 2001). All primer sets used have been
described previously (Westergaard et al, 2001) with the exception of
primer sets matching the inducible nitric oxide synthetase (iNOS) and
IL-6 genes: iNOS upstream primer, 50 -CAGCGCTACAACATCCTGGAGG-
30; iNOS downstream primer, 50 -GAGGGACCAGCCAA-ATCCAGTC-30
(iNOS, 30 cycles, 241 bp); IL-6 upstream primer, 50 -CCTTCGGTC-
CAGTTGCCTTCTC-30; IL-6 downstream primer, 50 -TTTTCTGCC-
AGTGCCTCTTTGC-30 (IL-6, 25 cycles, 241 bp). All reactions contained
the TBP primer set as an internal standard together with one additional
primer set.
Preparation of cytoplasmic and nuclear extracts and EMSA
Preparation of cytoplasmic and nuclear extracts from normal human
keratinocytes, treated or not with IL-1b and PPAR agonists as indicated,
and EMSA were performed as described previously (Johansen et al,
2000). The NF-kB consensus oligonucleotide (50 -AGTTGAGGGG-
ACTTTCCCAGGC-30) and the TFIID consensus oligonucleotide (50 -
GCAGAGCATATAAGGTGAGGTAGGA-30) were labeled as described by
the manufacturer (Promega, Madison,WI). Labeled oligonucleotides were
puri¢ed on a Nick Spin column (G-50, Pharmacia, Uppsala, Sweden).
Production of anti-PPARa and anti-PPARd antibodies For
production of the PPARa polyclonal antibody, 500 mg puri¢ed His-
tagged PPARawas mixed with 250 mL incomplete Freund’s adjuvant and
injected subcutaneously into a rabbit. Injections were repeated six times
with intervals of 14 d. Anti-PPARa antibodies were a⁄nity puri¢ed from
the antiserum. In short, immune serum was absorbed against GST
immobilized on glutathione-sepharose beads, and anti-PPARa antibodies
were subsequently a⁄nity-puri¢ed by binding to a GST-PPARa-A/B
domain fusion protein immobilized on CNBr-activated sepharose. Bound
antibodies were eluted with 0.1 mM glycineHCl (pH 2.8) and immedi-
ately neutralized in phosphate-bu¡ered saline (pH 7.6). The speci¢city
of the a⁄nity-puri¢ed anti-PPARa antibodies was assessed by western blot-
ting. Production and puri¢cation of polyclonal PPARd antibody was per-
formed as described elsewhere (Westergaard et al, 2001).
Western blotting Whole cell extracts were prepared using the TRIZOL
reagent according to the recommendation of the manufacturer (Gibco
BRL/Life Technologies). Blotting, enhanced chemiluminescence, and
stripping of membranes were performed as described previously
(Westergaard et al, 2001). For separation of PPARd, PPARg1, and
PPARg2, 40 mg of protein were separated in urea-containing minigels.
Detection of p50, p65, and IkBa in whole cell extracts was done by
separating 30 mg of protein in standard minigels. Cytoplasmic IkBa was
detected by separating 20 mg of protein on 8:16% gradient gels (Novex,
Frankfurt, Germany). Primary antibodies used were as follows: mouse
anti-PPARg (sc-7273, 1:1000) (this antibody is raised against the human
PPARgC-terminus, but recognizes all three PPAR subtypes), rabbit anti-
IkBa (sc-1643, 1:200), rabbit anti-NF-kB (p65) (sc-109, 1:200), rabbit anti-
NF-kB (p50) (sc-7178, 1:500), rabbit anti-TATA binding protein (TBP, sc-
273, 1:2000), and rabbit anti-TFIIB (sc-225, 1:2000), all Santa Cruz
Biotechnology, Santa Cruz, CA. Secondary antibodies were horseradish
peroxidase conjugated antimouse or antirabbit IgG antibodies (DAKO,
Glostrup, Denmark), diluted 1:2000.
Immunostaining Immunostaining of NF-kB (p65 or p50) in normal
human keratinocytes was performed as described previously (Westergaard
et al, 2001).The antibodies used were rabbit anti-NF-kB (p65) antibody (sc-
109, 1:100), rabbit anti-NF-kB (p50) (sc-7178, 1:500), and Alexa 488
conjugated goat antirabbit IgG (1:400) (Molecular Probes, Eugene, OR).
Nuclei were visualized by staining with Hoechst 33258 (Molecular Probes).
Immunohistochemistry Immunohistochemistry was performed as
described previously (Westergaard et al, 2001). Detection of PPARa,
PPARd, and PPARg was performed as described by Westergaard et al
(2001) using a⁄nity-puri¢ed PPARa- and PPARd-speci¢c antibodies and
a commercially available PPARg antibody (sc-6285), respectively. To detect
NF-kB (p65 or p50), sections were microwaved for 15 min in TEG bu¡er.
Blocking was performed overnight and sections were incubated with
antibodies at 41C overnight. The antibodies used were rabbit anti-NF-kB
(p65) antibody (sc-109, 1:500) and rabbit anti-NF-kB (p50) (sc-7178, 1:500).
In vitro protein^protein interaction assay (GST pull-down) GST
pull-down assays were performed essentially as described previously
(Kussmann-Gerber et al, 1999). Brie£y, for expression of the GST fusion
proteins Escherichia coli BL21-GROESL harboring the pGEX,
pGEXp65(1^305), or pGEXp65(354^551) expression constructs were used.
The GST fusion protein bound to glutathione-sepharose 4B beads was
incubated with 8 mL of in vitro translated 35S-methionine-labeled protein
in the presence of L165041 (1 mM) dissolved in DMSO or DMSO alone
in a total volume of 100 mL of incubation bu¡er (20 mM TrisHCl pH
8.0, 100 mM NaCl, 10 mM ethylenediamine tetraacetic acid, 0.5% Nonidet
P-40, 1 mM Dithioerythritol (DTE), 0.5 mM phenylmethylsulfonyl
£uoride, 1% skimmed milk, and protease inhibitors) and rotated for 2 h
at 41C. Following centrifugation the beads were washed four times in
incubation bu¡er with skimmed milk and once in incubation bu¡er
without skimmed milk. Beads were resuspended in 100 mL sodium
dodecyl sulfate (SDS) sample bu¡er, boiled for 5 min, and centrifuged.
The supernatant was loaded on an SDS-polyacrylamide gel. After drying,
the gels were exposed to a Phosphoimager screen and analyzed using the
ImageQuant program version 5.
Quantitation and statistical analysis TBP was used as the internal
standard for multiplex RT-PCR and expression from individual genes
was normalized to TBP. Quantitation was performed by phospho-
rimaging using the ImageQuant program version 5 (Molecular Dynamics).
For western blotting TFIIB was used as the internal standard and the level
of individual proteins was normalized to TFIIB. Quantitation was
performed by laser scanning densitometry using a Ultroscan XL 2222 and
the GelScan XL software package (Pharmacia LKB). Results are expressed
as mean7SD. For statistical analysis a one-way ANOVA was performed
followed by a Student t test. A probability of po0.05 was considered as
statistically signi¢cant.
RESULTS
Expression of PPAR in nonlesional and lesional psoriatic
skin We have shown that PPARd may play a role in control of
proliferation of basal cells and suggested that it serves as a
molecular switch involved in the initiation of keratinocyte
di¡erentiation (Westergaard et al, 2001). In addition, it was
reported that expression of PPARd mRNA tended to be
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upregulated in psoriatic skin (Rivier et al, 1998). Therefore, we
compared expression of the PPARs in nonlesional and lesional
skin in psoriasis patients. The skin samples were obtained either
as keratome biopsies of lesional and nonlesional skin in patients
with untreated psoriasis vulgaris, or as excision biopsies of
lesional psoriatic skin in patients before and after treatment at
the Dead Sea.
Total RNAwas isolated and expression of PPAR mRNAwas
determined by RT-PCR (Fig 1). These analyses revealed a 3^
5-fold upregulation of PPARd mRNA expression in lesional
psoriatic skin compared to nonlesional psoriatic skin (3.7-
fold70.67, po0.01) (Fig 1a). Similarly, robust upregulation of
PPARd mRNA expression was observed in RNA isolated from
biopsies of untreated lesional skin compared to post-treatment
biopsies (3.2-fold70.54, po0.01) (Fig 1b). No consistent changes
in the levels of PPARa mRNA were observed. The level of
PPARg mRNA tended to be slightly elevated in lesional
psoriatic skin. The levels of PPARg mRNA in all samples were
close to the detection limit, however. In untreated lesional
psoriatic skin the level of PPARg mRNA was higher in
excision biopsies than in keratome biopsies. This di¡erence may
be due to contaminating dermal tissue in the excision biopsies.
This may also explain the very low level of aP2 mRNA
expression observed in excision biopsies.
The expression of PPAR proteins was examined in lesional
psoriatic skin by western blotting. As shown in Fig 1(c), 1(d),
paralleling the results obtained by RT-PCR (Fig 1a, b), a 4^5-
fold upregulation of the PPARd protein was observed in
lesional psoriatic skin compared to nonlesional psoriatic skin (in
the matched pairs of lesional and nonlesional skin 4.4 -fold70.87,
po0.01; in the biopsies from pre- and post-treatment patients 4.1-
fold70.73, po0.01). In four of seven biopsy sets tested, we also
observed slightly elevated levels of the PPARg protein. The level
of PPARa was below the detection limit using this particular
antibody.
Immunohistochemical analyses of PPAR in nonlesional and
lesional psoriatic skin The distribution of PPARa, PPARd,
and PPARg in normal skin and nonlesional and lesional
psoriatic skin was determined by immunohistochemical analyses
(Fig 2). Most available PPAR antibodies exhibit subtype cross-
reactivity. Consequently, we tested a battery of di¡erent anti-
PPAR antibodies against 293 cells overexpressing each of the
human PPAR subtypes. Using this test the previously described
anti-PPARd antibody (Westergaard et al, 2001) was shown to
speci¢cally recognize PPARd. In addition, we found that a
polyclonal rabbit anti-PPARa antibody generated by immun-
ization with puri¢ed his-tagged full-length PPARa speci¢cally
recognized PPARa in immunohistochemistry. Finally, the
commercially available anti-PPARg antibody sc-6285 (Santa
Cruz Biotechnology) was found to be PPARg speci¢c in
immunohistochemistry (results not shown).
In normal skin, PPARa and PPARg exhibited a clear
cytoplasmic localization in the basal layer. In stratum spinosum
few cells exhibited nuclear localization of PPARa and PPARg,
whereas in stratum granulosum PPARa and PPARg pre-
dominantly localized to nuclei. PPARd was strongly expressed
in basal and suprabasal layers. Interestingly, in the basal layer,
PPARd intracellular localization varied in that PPARd exhibited
a cytoplasmic localization in a subset of cells and was present in
the nuclei of the remaining cells. In suprabasal cells, PPARd
localized predominantly to the nuclei both in stratum spinosum
and in stratum granulosum.
The intracellular distribution of the PPAR in nonlesional skin
from psoriasis patients resembled normal skin. In the thickened
epidermis of lesional psoriatic skin, the cytoplasmic localization
of PPARa and PPARg extended through most of the suprabasal
layers with only the outermost layer of suprabasal cells exhibiting
a nuclear localization. In contrast, PPARd localized to nuclei
throughout the entire suprabasal part of lesional psoriatic skin,
but maintained the mixed cytoplasmic and nuclear localization
in the basal layer.
Activation of PPAR subtypes by eicosanoids accumulating
in lesional psoriatic skin Psoriatic skin lesions are charac-
terized by the accumulation of numerous lipid chemoattrac-
tants (in£ammatory mediators) comprising di¡erent classes
of oxygenated fatty acid derivates, in particular lipoxygenase
Figure1. Expression of PPAR sub-
types in lesional and nonlesional psor-
iatic skin. Total RNA and protein were
prepared from (a), (c) biopsies of lesional
and nonlesional psoriatic skin from pa-
tients with psoriasis vulgaris or (b), (d)
biopsies of psoriasis patients before and
after treatment at the Dead Sea. (a), (b)
Multiplex RT-PCR analysis of the expres-
sion of PPARa, PPARd, PPARg1,
PPARg2, and aP2. TBP served as an inter-
nal control. (c), (d) Expression of PPARd
and PPARgwas analyzed by western blot-
ting. Forty micrograms of protein were
loaded in each lane. Protein extracts from
293 cells overexpressing PPARg2 or
PPARdwere used as positive controls. The
antibody used for detection (sc-7273) is di-
rected against the C-terminal region of
human PPARg, but recognizes also PPARd
(and PPARa). Expression of endogenous
PPARd is clearly detectable in 293 cells.
Equal loading/transfer was con¢rmed by
amido-black staining of membranes and
by immuno-detection of TFIIB.
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products. Thus, LTB4, the 5-, 8-, 9-, 11-, 12-, 15-hydro-
xyeicosatetraenoic acid (HETE), and 9- and 13-
hydroxyoctadecadienoic acid (HODE) have been reported to
accumulate in psoriatic skin with 12-HETE, 9-HODE, and 13-
HODE being the most abundant (Camp et al, 1983; Fogh et al,
1989). It has previously been shown that several of these
lipoxygenase products are able to enhance PPAR-mediated
transactivation (Yu et al, 1995; Devchand et al, 1996; Forman et al,
1997; Kliewer et al, 1997; Krey et al, 1997), and recently it was
shown that PPAR-mediated keratinocyte di¡erentiation was
impaired by lipoxygenase inhibitors (Thuillier et al, 2002).
Consequently, we examined the ability of the abundant
lipoxygenase products to activate the individual human PPAR
subtypes. As ligand selectivity and e⁄cacy may exhibit cell-type
speci¢city, ligand-dependent transactivation was tested in the
spontaneously transformed human keratinocyte HaCaT cell line,
previously shown to be an appropriate substitute for normal
human keratinocytes in transfection analyses (Westergaard et al,
2001). Similar to normal human keratinocytes, HaCaT cells have
a high basal level of activated extracellular signal-regulated kinase
1 (ERK1) and ERK2 resulting in a blunted ligand-dependent
activation of PPARg (Westergaard et al, 2001).
In agreement with previous observations, ligands only en-
hanced transactivation by full-length hPPARa or hPPARa(DAB)
2^3-fold (Westergaard et al, 2001), whereas ligand-dependent
activation of the hPPARa(LBD)/Gal4(DBD) fusion was much
more pronounced (Fig 3). All the tested HETEs modestly
enhanced transactivation by full-length hPPARa and
hPPARa(DAB). As reported earlier (Yu et al, 1995; Forman et al,
1997; Kliewer et al, 1997; Krey et al, 1997), 8(S)-HETE was found
to be a potent PPARa agonist. In addition, 12(R)-HETE and
15(S)-HETE markedly enhanced hPPARa(LBD)/Gal4(DBD)-
mediated transactivation. Interestingly, 13(S)-HODE potently
enhanced transactivation by full-length PPARawithout having
any e¡ect on transactivation mediated by hPPARa(DAB) and
hPPARa(LBD)/Gal4(DBD). Activation of the ERK-mitogen-
activated protein (ERK-MAP) kinases a¡ects PPAR-mediated
transactivation in part by phosphorylation of target residues in
the N-terminal A/B domains (Hu et al, 1996; Shalev et al, 1996;
Adams et al, 1997; Camp and Tafuri, 1997; Camp et al, 1999; Juge-
Aubry et al, 1999; Barger et al, 2000). Phosphorylation of PPARa
has been reported to enhance (Shalev et al, 1996; Juge-Aubry
et al, 1999) or repress (Barger et al, 2000) PPARa-mediated
transactivation. Similarly, 13(S)-HODE has been reported to
activate the ERK-MAP kinases (Hsi et al, 2001) or to repress
activation of the ERK2-MAP kinase (Mani et al, 1998). Hence, it
is possible that the 13(S)-HODE-induced transactivation by full-
length hPPARa is related to an e¡ect of 13(S)-HODE on ERK-
MAP kinase activation rather than 13(S)-HODE being a bona
¢de hPPARa ligand, or alternatively that a combination of the
two properties dictates the e¡ect of 13(S)-HODE on PPARa-
mediated transactivation.
PPARd was e¡ectively activated by 8(S)-, 12(S)-, 12(R)-, and
15(S)-HETE. In addition, 13(S)-HODE was a weak activator,
Figure 2. Immunohistochemical detection of
PPARs in normal, lesional, and nonlesional
psoriatic skin. Punch biopsies from lesional and
nonlesional psoriatic skin were analyzed for
expression and localization of PPARa, PPARd,
and PPARg using subtype-speci¢c anti-PPAR
antibodies as described in Materials and Methods.
All sections were counterstained with hematoxylin.
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whereas LTB4 did not enhance PPARd-mediated transactivation.
Finally, 8(S)-, 12(S)-, 12(R)-, and 15(S)-HETE, and LTB4
modestly induced PPARg1-mediated transactivation. Similar
results were obtained using PPARg2 (results not shown). As
noted above, the high levels of activated ERK-MAP kinases
blunted ligand-induced activation of the full-length PPARg,
and deletion of the AB domain enhanced ligand-induced
transactivation.
Ligand-dependent PPAR-mediated transactivation depends
on interaction with cofactors (Xu et al, 1999). We examined the
expression of a panel of known PPAR coactivators, p300,
CREB-binding protein (CBP), and steroid receptor coactivator
1, and corepressors, silencing mediator for retinoid and thyroid
hormone receptors and nuclear receptor corepressor, to
determine whether their expression was altered in lesional
psoriatic skin compared to nonlesional psoriatic skin. No
signi¢cant changes in the expression of mRNA encoding these
coactivators and corepressors were found (results not shown).
Recently, we showed that addition of the PPARd-selective
agonist L165041 to normal human keratinocytes induced
expression of the endogenous CD36/fatty acid transporter (FAT)
gene (Westergaard et al, 2001). The ability of PPARd-selective
ligands to induce CD36 expression in normal keratinocytes
combined with the increased levels of PPARd and PPARd
ligands in lesional psoriatic skin suggested that CD36 expres-
sion might be elevated in lesional psoriatic skin. In agreement
with this notion, multiplex RT-PCR revealed a pronounced
upregulation of CD36 mRNA expression in the biopsies of
lesional skin compared with matched biopsies of nonlesional
skin (8.1-fold73.4, po0.004) (Fig 4a). In the biopsies collected
before and after treatment at the Dead Sea a less pronounced
but still signi¢cant upregulation was also observed (2.4 -
fold70.84, po0.002) (Fig 4b). For comparison, expression of a
known marker for psoriatic lesional skin, E-FABP, was also
analyzed. Re£ecting the expression pattern of CD36, we found
a greater upregulation of E-FABP mRNA expression in the
biopsies of lesional skin compared with the matched biopsies of
nonlesional skin (3.6-fold70.86, po0.004) (Fig 4a) than in the
biopsies collected before and after treatment at the Dead Sea
(2.2-fold70.63, po0.002) (Fig 4b). The upregulation of CD36
expression in lesional psoriatic skin is compatible with an
enhanced PPARd-dependent induction of CD36 expression. As
the HETEs and HODEs that accumulate in psoriatic lesional skin
are also potent activators of the other PPAR subtypes (Fig 3),
however, contribution from PPARa and PPARg cannot be
excluded. It is also evident that numerous other factors may play
important roles in the upregulation of CD36 expression in
psoriatic lesional skin.
Analysis of NF-jB expression and intracellular localization
NF-kB has been implicated as a central player in the control of
epidermal proliferation and di¡erentiation, and based on the
phenotypes of transgenic knockout mice it was suggested that
NF-kB is involved either in the initiation of the di¡erentiation
process or in the maintenance of cell cycle withdrawal and the
di¡erentiated state (Klement et al, 1996; Hu et al, 1999; Li et al,
1999; Makris et al, 2000; Schmidt-Supprian et al, 2000). In
addition, IKKa appears to be critically involved in epidermal
di¡erentiation in a NF-kB-independent manner (Hu et al,
2001).
Figure 3. Di¡erential activation of PPARa, PPARd, and PPARc by eicosanoids present in lesional psoriatic skin.The subtype selectivity of the
selected eicosanoids was determined by transient transfections in HaCaT cells using either vectors encoding full-length PPAR, PPARwith deleted AB
domains, or Gal4 -PPAR(LBD) fusions with the appropriate luciferase reporter constructs. For analysis using full-length or PPARwith deleted AB domains
the following combinations (given per well) were used: hPPARa (0.01 mg), hPPARd (0.05 mg), hPPARg1 (0.05 mg), hPPARa(DAB) (0.01 mg), hPPARd(-
DAB) (0.05 mg), or hPPARg(DAB) (0.05 mg) with PPREx3-tk-luc reporter (0.75 mg) and a CMV-b-galactosidase construct (0.1 mg). For analysis using Gal4
fusions the following combinations (given per well) were used: hPPARa(LBD)/Gal4(DBD) (0.125 mg), hPPARd(LBD)/Gal4(DBD) (0.125 mg), or
hPPARg(LBD)/Gal4(DBD) (0.125 mg) with UASx4-tk-luc (0.75 mg) and a CMV-b-galactosidase construct (0.1 mg). In all transfections, empty expression
vector was added to ensure equal promoter load. Cells were incubated with medium containing 5 mM of 8(S)-HETE, 12(S)-HETE, 12(R)-HETE, 15(S)-
HETE, 13(S)-HODE, LTB4, or 100 mM Wy14643, 1 mM BRL49653, 10 nM L165041, or vehicle (0.1% DMSO) for approximately 16 h prior to harvest.
Reporter activity was normalized to b-galactosidase values. All transfections were performed independently a minimum of four times in duplicate. Results
are presented as mean7SD. An asterisk indicates signi¢cant deviation from the vehicle-treated controls (po0.05).
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No comprehensive analysis of NF-kB expression and intra-
cellular localization in normal, nonlesional, and lesional psoriatic
skin has been presented, and given the reported e¡ects of PPARs
and PPAR ligands on NF-kB-dependent processes, we analyzed
whether NF-kB expression and intracellular localization were
altered in lesional psoriatic skin compared with nonlesional and
normal skin.
NF-kB in skin consists predominantly of p50/p50 homodimers
or p50/p65 heterodimers, with p50/p50 homodimers prevailing
(Budunova et al, 1999; results not shown). Western blotting of
whole cell extracts revealed no signi¢cant overall alterations in
the expression of the p65 and p50 subunits of NF-kB and IkBa
in lesional psoriatic skin compared with nonlesional skin. By
densitometric scanning the ratio between expression in lesional
and nonlesional skin was determined to be 0.9670.10 for p50,
1.1070.39 for p65, and 1.0370.23 for IkBa (Fig 5).
Immunohistochemical analyses revealed that normal
interfollicular human skin displays a characteristic intracellular
distribution of p50 and p65 (Fig 6). In the basal layer there is a
cytoplasmic accumulation of p50 with few cells exhibiting
nuclear localization of p50. In the suprabasal layers most cells
contain nuclear p50. In contrast, p65 exhibits exclusively a
cytoplasmic localization in both the basal layer and the
suprabasal layers. In total, specimens from six di¡erent
individuals with no history of psoriasis were analyzed, and all
displayed this characteristic distribution. Next specimens of skin
from ¢ve patients with chronic psoriasis were analyzed. In these
¢ve specimens we found virtually the same intracellular
distribution of p50 and p65 in nonlesional skin. In lesional skin
strong nuclear staining of p50 was observed in the outermost
suprabasal layer whereas fewer cells in the lower parts of the
suprabasal layer exhibited a nuclear localization of p50. A priori
we would have expected a nuclear localization of p65 in lesional
skin due to in£ammation and accumulation of proin£ammatory
cytokines known to induce nuclear translocation of NF-kB. In
none of the ¢ve specimens did we observe nuclear accumulation
of p65 in lesional skin, however. Thus, our results clearly
demonstrate that persistent nuclear localization of p65 is not a
hallmark of psoriasis. This conclusion was corroborated by gel
shift analyses showing that nuclear extracts from normal,
nonlesional, and lesional psoriatic skin only revealed DNA
binding of the p50/p50 homodimer (Johansen et al, manuscript
in preparation).
Physical and functional interaction between PPAR and
NF-jB Substantial evidence has accumulated that PPARa
and PPARg or their ligands directly or indirectly are involved in
the modulation of NF-kB activity (Poynter and Daynes, 1998;
Delerive et al, 1999; 2000; Su et al, 1999; Chung et al, 2000; Li
et al, 2000b). PPARd expression is upregulated in psoriatic lesions,
and even though PPARd predominantly localized to nuclei in the
suprabasal layer of lesional psoriatic skin, clear cytoplasmic
staining was also observed (Fig 2). This fact combined with the
¢ndings that several of the hydroxylated fatty acids that
accumulate in psoriatic lesions are potent PPARd agonists
prompted us to investigate whether PPARd like PPARa and
PPARg interacts with p65 and whether the accumulation of
PPARd ligands might interfere with cytokine-induced nuclear
accumulation of NF-kB. To address these questions we ¢rst
employed GST pull-down experiments to determine if PPARd
also interacts with the p65 subunit of NF-kB. Figure 7 shows
that full-length PPARd interacted strongly and speci¢cally with
the N-terminal part of p65 containing the Rel homology region
mediating DNA binding, dimerization, and IkBa interaction.
Furthermore, deletion of the AB domain of PPARd did not
impair interaction with p65. Interaction was ligand independent
(results not shown). Thus it appears that all PPAR subtypes are
able to interact directly with p65.
Next we investigated whether PPAR agonists a¡ected IL-1b-
induced translocation and DNA binding of NF-kB human
keratinocytes (Fig 8). In growing nontreated cells p50 (Fig 8a)
and p65 (Fig 8b) exhibited a cytoplasmic localization similar to
that observed in proliferating basal cells. IL-1b treatment induced
nuclear translocation of both p50 and p65. Preincubation with
PPARa-, PPARd-, or PPARg-selective agonists for 24 h or 1 h
(results not shown) did not signi¢cantly a¡ect the IL-1b-
induced nuclear translocation of p50 and p65. Accordingly,
IL-1b-induced degradation of IkBa was not a¡ected by
Figure 4. Elevated expression of CD36 mRNA in lesional psoriatic skin. Total RNA was prepared from (a) biopsies of lesional and nonlesional
psoriatic skin from patients with psoriasis vulgaris or (b) biopsies from psoriasis patients before and after treatment at the Dead Sea. The expression of
CD36 (FAT) was determined by multiplex RT-PCR. The expression of epidermal fatty acid binding protein (E-FABP) served as a positive control for
lesional psoriatic skin (Madsen et al, 1991), and expression of TBP served as an internal control.
Figure 5. Analysis of NF-jB and IjBa expression in lesional and
nonlesional psoriatic skin. Whole cell protein extracts were prepared
from lesional and nonlesional psoriatic skin from patients with psoriasis
vulgaris, and analyzed for expression of the NF-kB subunits p65 and p50
and IkBa by Western blotting. Thirty micrograms of total protein were
applied per lane and equal loading/transfer was con¢rmed by amido-black
staining of membranes and by immuno-detection of TFIIB.
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administration of PPAR agonists (Fig 9a). It has been reported
that PPAR agonists may interfere with NF-kB activation
without interfering with nuclear translocation by impairing
NF-kB DNA binding (Delerive et al, 2000). In keratinocytes this
appears not to be the case. Treatment with IL-1b induced a rapid
and transient increase in NF-kB DNA-binding activity, and
preincubation for 24 h or 1 h (results not shown) with PPAR
agonists did not reduce IL-1b-induced NF-kB binding ^ if
anything, it appeared that preincubation with the PPARa
agonist enhanced NF-kB DNA binding. Binding to an oligo-
nucleotide containing a consensus TATA box was una¡ec-
ted by IL-1b and PPAR ligands (Fig 9b).
Physical interaction and reciprocal transcriptional regulation
have been described between NF-kB and PPARa and PPARg
in macrophages, COS-1, and HeLa cells (Delerive et al, 1999;
Chung et al, 2000; Li et al, 2000b). Consequently, we analyzed
whether reciprocal functional interaction between PPARd and
p65 or p50 could be observed in primary human keratinocytes.
In the ¢rst set of experiments a reporter construct containing
three copies of the kB site was transfected with di¡erent
combinations of vectors expressing p65 or PPAR. Figure 10
shows that p65 strongly activated the reporter. Either PPAR
subtype alone had no e¡ect, and, interestingly, even a 30-fold
molar excess of the PPAR-expressing vectors did not reduce the
p65-dependent transactivation whether or not a PPAR-selective
agonist was present. On the contrary, coexpression of PPARs
tended to slightly increase p65-mediated transactivation in a
concentration-dependent manner. Essentially the same results
were obtained using a reporter construct containing part of the
proximal IL-6 promoter with coexpression of p65 and PPARd
(results not shown). Forced expression of p50 did not result in
activation of the NF-kB-responsive reporter construct, neither
in the presence nor in the absence of coexpressed PPARs (results
not shown). Contrasting the e¡ect of PPARs on p65-driven
transactivation, PPAR-mediated ligand-dependent and ligand-
independent activation of a reporter driven by three copies of
the PPRE from the acyl-CoA oxidase gene were strongly and
concentration-dependently repressed by expression of p65 (Fig
11a). Noteworthy, p50 coexpression did not repress PPAR-
mediated transactivation (Fig 11b). The p65-dependent repres-
sion of PPAR-mediated transactivation takes place in the absence
of known kB sites in the reporter construct. The e¡ect of p65 is
not general as expression of b-galactosidase from the normalizing
vector was una¡ected, and furthermore p65 did not exert the
same repressive action on SREBP-1a-mediated transactivation
(results not shown).
As coexpression of PPARs and/or administration of PPAR
agonists did not repress p65-mediated transactivation, PPAR
Figure 6. Localization of NF-jB p50 and p65
in normal, lesional, and nonlesional psoriatic
skin. Immunohistochemical analysis of NF-kB
(p50 and p65) expression and localization in
punch biopsies from normal, lesional, and nonle-
sional psoriatic skin. In total specimens from six
control patients with no history of psoriasis and
¢ve patients with chronic psoriasis were analyzed.
A uniform pattern of p50 and p65 distribution
was found in all control specimens with cytoplas-
mic sequestering of p50 and p65 in the basal layer,
whereas nuclear localization of p50 was observed
in the suprabasal layers. Unexpectedly, no nuclear
accumulation of p65 was observed in the epider-
mis of patients with chronic psoriasis. The paraf-
¢n-embedded sections were counterstained with
hematoxylin.
Figure 7. In vitro interaction between hPPARd and the p65 subunit of NF-jB. Full-length and DAB hPPARdwere synthesized in the presence of
[35S]methionine by in vitro translation and analyzed with either GST-p65 (residues 1^305) or GST-p65 (residues 354^551) bound to glutathione-sepharose
beads as baits in pull-down assays (see Materials and Methods for details).
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agonists should not decrease IL-1b-induced expression of an NF-
kB-responsive reporter gene in keratinocytes. To test this, cells
were transfected with the NF-kB-responsive reporter, left for
7 h, and then pretreated or not for 2 h with BRL49653 or
L165041 before IL-1bwas added. The cells were harvested after a
further 3 h of incubation. Figure 12(a) shows that treatment with
IL-1byielded a robust induction of reporter gene expression.This
induction was not signi¢cantly repressed by pretreatment with
L165041 or BRL49653. As the e¡ect of PPAR ligands on NF-
kB-responsive genes may be chromatin and/or promoter context
dependent (Delerive et al, 2002), we analyzed the e¡ect of PPAR
agonists on IL-1b-induced expression of two endogenous NF-
kB-responsive genes, the iNOS gene and the IL-6 gene. Figure
12(b) shows that expression of both genes is strongly induced by
IL-1b, and preincubation with the PPARd- or the PPARg-
selective agonist did not impair induction. In conclusion, PPAR
expression or administration of PPAR agonists did not impair
the ability of the proin£ammatory cytokine IL-1b to induce
p65-dependent transactivation in keratinocytes. In contrast, p65
is a potent inhibitor of ligand-independent as well as ligand-
dependent transactivation mediated by all three PPAR sub-
types.
p65-dependent repression of PPAR-mediated transactivation is
not unique to keratinocytes but is also observed in other cell
types examined, including COS-1 cells and 293 cells (Delerive et al,
1999; S. Rasmussen, J. Henningsen, M.Westergaard, K. Kristiansen,
unpublished results). To examine if sequestering of coactivators
contributes to the p65-dependent repression of PPAR-mediated
transactivation, we investigated the e¡ect of increasing
expression of CBP and p300 on p65-dependent repression of
PPAR-mediated transactivation. Cotransfection with an equi-
molar amount of the CBP expression vector slightly increased
PPARa-, PPARd-, and PPARg-mediated transactivation, where-
as greater amounts of the cotransfected CBP expression vector
reduced transactivation mediated by all PPAR subtypes.
Cotransfection with a vector expressing p300 repressed PPARa-
and PPARg-mediated transactivation even at the lowest amount
of cotransfected p300 expression vector. In contrast, coexpression
of p300 enhanced PPARd-mediated transactivation. Interestingly,
forced expression of either CBP or p300 in a concentration-
dependent manner partially rescued PPAR-mediated trans-
activation in the presence of coexpressed p65, with rescue of
PPARd- and PPARa-mediated transactivation being the most
prominent (Fig 13). The interpretation of coactivator titration
experiments is di⁄cult as the endogenous levels of the
ectopically expressed coactivators as well as the levels of
numerous other cofactors that interact with the PPARs and p65
dictate the response. Our results indicate, however, that
competition for coactivators contributes to, but is not the sole
phenomenon responsible for, p65-dependent repression of
PPAR-mediated transactivation.
DISCUSSION
It is well established that classical nuclear receptors play impor-
tant roles in the epidermis, and during the last couple of years
members of the PPAR family have been added to the growing
list of nuclear receptors involved in keratinocyte di¡erentiation
and function (Hanley et al, 1997; 1998; 1999; Rivier et al, 1998; Ko-
muves et al, 2000a; 2000b). Recently, PPARa and PPARd were
shown to play pivotal roles in controlling in£ammation, migra-
tion, survival, and di¡erentiation of keratinocytes during wound
healing in mice (Michalik et al, 2001;Tan et al, 2001). Interestingly,
all PPAR subtypes are expressed during fetal development of the
skin in mice, but expression in the interfollicular epidermis ceases
shortly after birth (Michalik et al, 2001). Expression of PPARa
and PPARd in the adult epidermis is induced in response to in-
£ammation, however (Michalik et al, 2001). In contrast, all PPAR
subtypes are expressed in interfollicular human epidermis, with
PPARd being by far the predominant subtype (Rivier et al, 1998;
Westergaard et al, 2001; this paper).
Figure 8. The e¡ect of PPAR agonists
on IL-1b-induced nuclear translocation
of NF-jB. Immuno£uorescence analysis of
the intracellular localization of (a) the p50
and (b) the p65 subunit of NF-kB in normal
human keratinocytes preincubated for 24 h
with Wy14643 (10 mM), L165041 (5 nM),
BRL49653 (1 mM), or vehicle (0.1% DMSO)
prior to IL-1b treatment for 30 min as de-
scribed in Materials and Methods. The p50
and p65 subunits of NF-kB were visualized
by indirect immuno£uorescence microscopy.
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In this study we show that expression of PPARd is dramati-
cally upregulated at the mRNA as well as at the protein level in
hyperproliferative lesional skin from psoriasis patients. This up-
regulation is probably related to the accumulation of proin-
£ammatory cytokines in the psoriatic lesions in analogy with
the in£ammation-dependent upregulation of PPARd expression
in mouse skin (Tan et al, 2001). A detailed immunochemical ana-
lysis of the intracellular distribution of PPAR subtypes revealed
no marked disturbances comparing normal, nonlesional, and
lesional psoriatic skin. In particular, PPARd exhibited a nuclear
localization in the entire suprabasal region of normal and psoria-
tic skin, whereas two populations of cells were present in the ba-
sal layer, one exhibiting nuclear localization of PPARd and one
exhibiting a cytoplasmic accumulation of PPARd.
Lesional psoriatic skin is characterized by the accumulation
of numerous in£ammatory lipoxygenase products. By transient
transfections in HaCaT cells, we showed that human PPARdwas
potently activated by 8(S)-HETE, 12(S)-HETE, 12(R)-HETE,
and 15(S)-HETE. Of these, 12(R)-HETE in particular has been
shown to accumulate to high levels in lesional psoriatic skin
(Woollard, 1986). Upregulation of PPARd expression combined
with high abundance of potent agonists would suggest that
PPARd-responsive genes might be upregulated in lesional psoria-
tic skin.We have presented evidence that CD36/FAT is a PPARd-
responsive gene in human keratinocytes (Westergaard et al, 2001).
In keeping with this notion, we now demonstrate a signi¢cant
upregulation of CD36/FAT expression in lesional psoriatic skin.
Thus, our results suggest that PPARd-mediated transactivation is
enhanced in lesional psoriatic skin.
Members of the NF-kB/Rel family of transcription factors are
pleiotropic regulators of cellular growth and homeostasis (Ghosh
and Karin, 2002). Recently, NF-kB was also implicated as a pivo-
tal regulator of epidermal proliferation and di¡erentiation (for re-
views see Kaufman and Fuchs, 2000; Fuchs and Raghavan, 2002),
even though the precise function of NF-kB in epidermal home-
ostasis remains enigmatic. It is evident that forced expression of
an arti¢cial transactivating form of p50 or p65 in the basal layer
of mouse epidermis leads to cell cycle arrest, hypoplasia, and
accelerated di¡erentiation (Seitz et al, 1998; 2000a). Conversely,
epidermis-speci¢c abrogation of NF-kB activation by forced ex-
pression of a nondegradable form of IkBa has been shown to be
associated with hyperplasia and hyperkeratinization (Seitz et al,
1998). It is unclear, however, whether the observed hyperplasia
represents a keratinocyte-cell-autonomous phenomenon or is a
secondary e¡ect related to altered immune homeostasis. This as-
pect was underscored by the interesting ¢nding that mice with
an epidermis-speci¢c deletion of IKK2 (IKKb) were born with
a normal skin but developed a severe in£ammatory dermatitis
during the ¢rst week after birth (Pasparakis et al, 2002). Along
the same line, lack of IKK1 (IKKa) resulted in epidermal hyper-
plasia and severely impaired di¡erentiation, which could be res-
cued by a kinase-inactive IKK1 (IKKa) mutant, and it was shown
that expression of IKK1 (IKKa) led to the synthesis of a polypep-
tide that stimulated keratinocyte di¡erentiation independently of
NF-kB activation (Hu et al, 2001). Taken together these results
clearly indicate that the role of the NF-kB system in skin home-
ostasis is far more complex than ¢rst anticipated. Indeed it is pos-
sible that NF-kB activation plays a minor role in the normal
development of interfollicular skin. Thus, by using a transgenic
mouse model harboring an integrated NF-kB reporter, no NF-
kB-dependent transactivation was observed in the interfollicular
epidermis (Schmidt-Ullrich et al, 2001). A lack of NF-kB-
mediated transactivation would also be consistent with our ¢nd-
ing that only p50 exhibits a nuclear localization in the suprabasal
layer of normal skin, and normally, p50/p50 homodimers repress
rather than stimulate transcription (Ghosh and Karin, 2002). This
said, it should be mentioned that convincing evidence has been
presented that NF-kB plays an antiapoptotic role in the epidermis
(Seitz et al, 2000b; Qin et al, 2001). The same was shown in the
case of PPARd during wound healing and in response to stimu-
lation by proin£ammatory cytokines (Tan et al, 2001; Di-Po|« et al,
2002).
NF-kB-mediated transactivation has been shown to be re-
pressed by PPARa and PPARg or PPARa or PPARg agonists
in several cell types (Jiang et al, 1998; Ricote et al, 1998; Staels
et al, 1998; Delerive et al, 1999; Chung et al, 2000; Li et al, 2000b).
Interestingly, it was recently demonstrated that PPARa could po-
sitively a¡ect NF-kB-dependent induction of IkBa expression,
suggesting that the e¡ect of PPAR on NF-kB-mediated transac-
tivation exhibits cell type and/or promoter dependence (Delerive
et al, 2002). Our results demonstrate that all PPAR subtypes in
the absence or presence of agonists in keratinocytes are unable to
repress p65-mediated activation of an NF-kB-responsive reporter.
In fact, a slight concentration-dependent activation was obser-
ved. Conversely, we observed a very strong downregulation of
ligand-independent and ligand-dependent PPAR-mediated
Figure 9. PPAR agonists do not prevent IL-1b-induced degradation
of IjBa or NF-jB DNA binding in normal human keratinocytes.
(a) Cytoplasmic extracts or (b) nuclear protein extracts were isolated from
normal human keratinocytes preincubated for 24 h with vehicle (0.1%
DMSO),Wy14643 (10 mM), L165041 (5 nM), or BRL49653 (1 mM) prior
to stimulation with IL-1b (see Materials and Methods for details). (a) Twenty
micrograms of cytoplasmatic protein were separated in SDS-polyacryla-
mide gels and the level of IkBawas determined by western blotting. Equal
loading/transfer was con¢rmed by amido-black staining (not shown) of
membranes and by immuno-detection of TFIIB. The n.s. denotes a non-
speci¢c band. (b) EMSAwere performed using a double-stranded oligonu-
cleotide harboring a consensus kB element or a consensus TATA box.
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transactivation by coexpression of p65, but not p50. The fact that
forced expression of the coactivators CBP or p300 partially res-
cues the PPAR-mediated transactivation suggests that coactivator
sequestering at least in part is responsible for the p65-dependent
repression. Generally, considering cross-talk between PPAR and
NF-kB most emphasis has been on the e¡ects of PPARor PPAR
ligands on NF-kB. Our ¢ndings suggest that the reverse situa-
tion, namely p65-dependent inhibition of PPAR-mediated trans-
activation, should be considered as an important facet in the
regulation of PPAR-dependent processes; and p65-dependent
downregulation of PPAR-mediated transactivation is not re-
stricted to keratinocytes but is also observed in several other cell
types (Delerive et al, 1999; S. Rasmussen, J. Henningsen, M.Wes-
tergaard, K. Kristiansen, unpublished results). The ability of p65
to downregulate PPARd-mediated transactivation is also intri-
guing and paradoxical considering that PPARdvia transcriptional
Figure10. p65-mediated transactivation is not suppressed by coexpression of PPAR in the absence or presence of PPAR agonists in normal
human keratinocytes. Normal human keratinocytes were transiently transfected with the p(kB)3-lucþ reporter (50 ng), with di¡erent combinations of
expression vectors p65 (6 ng) and hPPARa, hPPARd, or hPPARg1 (18 ng or 60 ng). Mediumwas changed after 6 h, and the cells were subsequently treated
with medium containingWy14643 (10 mM), L165041 (5 nM), BRL49653 (1 mM), or vehicle (0.1% DMSO) for approximately 20 h prior to harvest. In all
transfections empty expression vector was added to ensure equal promoter load and an SV40-b-galactosidase construct was used for normalization. Reporter
activity was normalized to b-galactosidase values and fold induction is presented as the mean7SD. Transfections were performed in triplicate, measured in
duplicate, and repeated four times. One representative experiment is presented.
Figure11. The p65, but not the p50, subunit of NF-jB potently suppresses PPAR-mediated transactivation in normal human keratinocytes.
Normal human keratinocytes were transiently transfected with PPREx3-tk-luc (160 ng) with di¡erent combinations of expression vectors. (a) hPPARa
(0.625 ng), hPPARd (62.5 ng), hPPARg1 (62.5 ng), and increasing amounts of p65 (0.1, 0.5, 2.5, and 12.5 ng). (b) As (a) but with increasing amounts of p50
using the following combinations: hPPARa (0.625 ng), PPREx3-tk-luc reporter (160 ng), and p50 (0.1, 0.5, 2.5 ng); hPPARd (20 ng), PPREx3-tk-luc (130
ng), p50 (3.2, 16, 80 ng), or hPPARg1 (40 ng), PPREx3-tk-luc reporter (102.5 ng), p50 (6.4, 32, 160 ng). Medium was changed after 6 h, and the cells were
subsequently treated with medium containingWy14643 (10 mM), L165041 (5 nM), BRL49653 (1 mM), or vehicle (0.1% DMSO) for approximately 20 h prior
to harvest. In all transfections empty expression vector was added to ensure equal promoter load and an SV40-b-galactosidase construct was used for
normalization. Reporter activity was normalized to b-galactosidase values and fold induction is presented as the mean7range. Transfections were
performed in duplicate, measured in duplicate, and repeated four times. One representative experiment is presented.
1114 WESTERGAARD ETAL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
induction of ILK and PDK1was reported to increase Akt1 activ-
ity leading to enhanced NF-kB activity in keratinocytes (Di-Po|«
et al, 2002).
In normal skin the absence of nuclear p65 allows PPAR-de-
pendent transactivation, and the presence of nuclear p50 does
not seem to repress PPAR-dependent gene expression, and hence
PPARd may exert its pro-di¡erentiating actions. In chronic psor-
iatic lesions p65 remains in the cytoplasm in spite of the massive
accumulation of proin£ammatory cytokines allowing PPARd-
dependent gene activation. Considering the severe e¡ects on epi-
dermal proliferation and di¡erentiation associated with defects in
NF-kB activation in keratinocytes, it is tempting to speculate that
the absence of NF-kB activation in chronic psoriatic plaques con-
tributes to the hyperproliferative and di¡erentiation-de¢cient
phenotype of psoriasis.
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